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AbstrACt
Introduction Low quality of life is common in cancer 
survivors. Increasing physical activity, improving diet, 
supporting psychological well-being and weight loss 
can improve quality of life in several cancers and may 
limit relapse. The aim of the randomised controlled 
trial outlined in this protocol is to examine whether a 
digital intervention (Renewed), with or without human 
support, can improve quality of life in cancer survivors. 
Renewed provides support for increasing physical activity, 
managing difficult emotions, eating a healthier diet and 
weight management.
Methods and analysis A randomised controlled trial 
is being conducted comparing usual care, access to 
Renewed or access to Renewed with brief human support. 
Cancer survivors who have had colorectal, breast or 
prostate cancer will be identified and invited through 
general practice searches and mail-outs. Participants 
are asked to complete baseline measures immediately 
after screening and will then be randomised to a study 
group; this is all completed on the Renewed website. 
The primary outcome is quality of life measured by the 
European Organization for Research and Treatment of 
Cancer QLQ-c30. Secondary outcomes include anxiety 
and depression, fear of cancer recurrence, general well-
being, enablement and items relating to costs for a health 
economics analysis. Process measures include perceptions 
of human support, intervention usage and satisfaction, and 
adherence to behavioural changes. Qualitative process 
evaluations will be conducted with patients and healthcare 
staff providing support.
Ethics and dissemination The trial has been approved 
by the NHS Research Ethics Committee (Reference 18/
NW/0013). The results of this trial will be published 
in peer-reviewed journals and through conference 
presentations.
trial registration number ISRCTN96374224; Pre-results.
IntroduCtIon  
Population-based studies indicate that quality 
of life (QoL) is poor in as many as one-third 
of cancer survivors post-treatment,1 with 
levels equivalent to those in people living with 
major chronic diseases.2 3 Those who struggle 
with aspects of QoL after treatment experi-
ence particular problems with psychological 
distress and fatigue2 and social, physical and 
financial consequences,4 5 which can persist 
for 10 years or more post-treatment.5 This is a 
significant concern given the rising prevalence 
of secondary cancers due to heightened life 
expectancy and common environmental and 
lifestyle factors associated with increased risk, 
such as unhealthy diet.6–8 Up to 75% of survi-
vors of cancer also then struggle with comorbid 
issues such as arthritis, high blood pressure and 
anxiety and depression, which contribute to 
poorer quality of life.9 Evidence suggests that 
early intervention could alleviate some longer 
term problems and reduce burden on the 
health service10 and that specifically addressing 
physical activity, psychological well-being, diet 
strengths and limitations of this study
 ► The intervention is designed to be easy to imple-
ment at scale.
 ► The intervention was developed using evidence-, 
theory- and person-based approaches.
 ► This trial will only be able to explore effects in pa-
tients with breast, colorectal and prostate cancer. 
However, this will enable exploration of whether the 
intervention might be a viable form of support for 
survivors of other forms of cancer.
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and weight loss is likely to improve QoL in survivors of a 
range of cancers and may limit relapse.11–14 
Physical activity
The positive effects of physical activity in cancer survivors 
are well documented. Meta-analyses indicate that phys-
ical activity interventions reduce fatigue in cancer survi-
vors.15–18 Overall, positive trends and impact of physical 
activity interventions exist for physiological, psychosocial 
and functional outcomes.19 20 As a result, being suffi-
ciently active is one of the cornerstones of a long-term 
self-care strategy for cancer survivors.21
Psychological Well-being
The psychological well-being of cancer survivors can be 
enhanced through a range of approaches. Cognitive 
behavioural therapy (CBT) techniques aimed at survivors 
have been found to significantly reduce psychological 
distress, including depression and anxiety.22 Mindful-
ness-based interventions place emphasis on the accep-
tance and awareness of the present through the use of 
mindfulness techniques, including meditation exer-
cises.23 Review evidence indicates mindfulness-based 
techniques can reduce stress and anxiety in breast cancer 
survivors24 and improve QoL in cancer survivors, often by 
improving fear of cancer recurrence, stress, anxiety and 
depression.25 Mindfulness-based interventions also effec-
tively reduce cancer-related fatigue.26 27
diet
Improving diet can positively impact the health and 
well-being of cancer survivors. Lowering fat consump-
tion reduces cancer relapse28 and data from the Healthy 
Survey for England indicates an association between 
increased fruit and vegetable intake and reduced cancer 
mortality. Systematic review evidence also indicates that 
healthy dietary changes improve health-related QoL in 
cancer survivors.29
Weight management
Being overweight or obese is common among cancer survi-
vors15 and associated with negative health and well-being 
consequences, including risk of cancer recurrence.30 31 
Review evidence suggests that weight loss is feasible and 
safe for cancer survivors.32 In addition, breast cancer-re-
lated biomarkers reduced by 30%–40% in breast cancer 
survivors who lost 5% or more of their body weight, indi-
cating a lower risk of cancer recurrence.30 Weight loss also 
has a positive effect on QoL in cancer survivors.32
using the internet
The current study will evaluate a digital intervention created 
specifically to improve QoL in cancer survivors. A digital 
intervention is likely to be an efficient and cost-effective mode 
of delivery of an intervention to support cancer survivors in 
improving their QoL. The internet is now used extensively 
and successfully by older adults for disease self-management33 
and a recent review found that internet-based interventions 
can be as effective as face-to-face therapy, becoming a viable 
cost-effective alternative.34
AIMs And hyPothEsEs
The aim of the Renewed trial is to evaluate the effective-
ness and cost-effectiveness of two trial arms using an inter-
vention designed to improve QoL in breast, colon and 
prostate cancer survivors: the first arm will be given access 
to a digital intervention (Renewed) and the second will 
be given access to Renewed accompanied by brief human 
support.
The research aims to answer the following questions:
Primary research question
1.Does the Renewed intervention, with or without human 
support, result in a difference in QoL (as measured by 
the European Organization for Research and Treatment 
of Cancer (EORTC) QLQ-c30;35) at 6 month follow-up 
compared with treatment as usual?
secondary research questions
1. Does the Renewed intervention, with or without hu-
man support, result in a difference in QoL at 12 month 
follow-up compared with treatment as usual?
2. Is the Renewed intervention, with or without human 
support, more cost-effective than usual care in improv-
ing QoL in cancer survivors?
3. Does the Renewed intervention, with or without hu-
man support, result in a difference in psychological 
and overall well-being (including low mood and fear 
of cancer recurrence) at 6 month and 12 month fol-
low-up?
4. Does the Renewed intervention, with or without hu-
man support, help to reduce the risk of secondary can-
cers (recurrence, metastatic cancer or another form of 
cancer)?
Qualitative process analysis research questions
1. Is the Renewed intervention, with or without hu-
man support, acceptable to patients and healthcare 
practitioners?
2. Is the Renewed support feasible for healthcare practi-
tioners to implement in practice?
MEthods
study design
The Renewed study is a pragmatic, randomised controlled 
trial comparing usual care, the Renewed intervention and 
Renewed accompanied by brief human support. The long-
term aim of the intervention is to potentially help cancer 
survivors with other forms of cancer. At this stage, we 
have chosen three contrasting common survivor groups, 
who have no metastatic disease, to deal with the likely 
varying issues in needs and preferences across gender 
and age spectrums: breast cancer survivors (younger and 
older women); prostate cancer survivors and those on 
active surveillance/watchful waiting for prostate cancer 
(predominantly older men); and colorectal cancer (a 
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range of age and gender). By working with these groups, 
we will explore to what extent the intervention is likely to 
be generalisable to other survivor groups. See figure 1 for 
an outline of the flow of the study.
Patient and public involvement
When first designing the study, the research team received 
input from six patient representatives who had experi-
enced breast, prostate or colorectal cancer, in addition to 
members of Macmillan Cancer Support, Prostate Cancer 
UK, Breast Cancer Care, Bowel Cancer UK, Cancer 
Research UK and the National Cancer Research Institute. 
All parties had input into the original grant proposal and 
played a part in developing and agreeing the research 
questions, study procedures (eg, inclusion criteria) and 
choice of primary outcome.
After securing funding, an additional two patient repre-
sentatives were recruited to replace two patient representa-
tives who were unable to continue their involvement due to 
ill health. Our panel of six patient representatives and repre-
sentatives from Prostate Cancer UK, Breast Cancer Care and 
Bowel Cancer UK are part of the study management team 
and attend regular meetings to contribute to the develop-
ment of the Renewed intervention and the study protocol 
and procedures for the randomised controlled trial. They 
Figure 1 Randomised controlled trial and pilot study procedure flow chart. GP, general practitioner; NHS, National Health 
Service; QoL, quality of life.
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assisted in refining the study design, for example, making 
suggestions for the frequency and mode of support delivery 
for patients randomised to the support arm, which were 
implemented. The patient representatives also took part 
in qualitative interviews and provided detailed comments 
on draft intervention materials (in addition to feedback 
obtained by qualitative interviews with 33 research partic-
ipants recruited from primary care (see Bradbury et al, in 
prep). This feedback was used to inform modifications to 
the intervention to maximise engagement and minimise 
any burden posed by the intervention.
At the end of data collection, patient and charity repre-
sentatives will be involved in the discussion and inter-
pretation of the trial and process evaluation data and in 
planning dissemination with stakeholders.
recruitment
Participants (n=2500) will be recruited across England 
and Wales from sites in Southampton, Oxford and 
Bangor, via general practitioner (GP) surgery mail-outs. 
Practices will be informed about the study via clinical 
research networks and practices who opt-in can proceed 
to participate. Practice staff will search GP databases for 
eligible patients (see table 1 inclusion/exclusion criteria).
Lists of potentially eligible patients will be screened 
by GPs prior to mail-out. Anonymous data (age, cancer 
type, postcode and diagnosis date) will be collected via 
GP record searches on all invited patients to allow explo-
ration of the generalisability of our sample.
Patients will be mailed a letter of invitation, an infor-
mation sheet, instructions on how to start the study and 
a reply slip collecting reasons for non-participation. 
Opportunistic recruitment by clinicians in participating 
surgeries will also be used to recruit patients who fit the 
inclusion criteria. Posters advertising the study may also 
be presented in waiting areas. The expected dates of 
recruitment run from October 2017 until July 2019.
Eligibility criteria
See table 1. We will be using a cut-off of 85 on the primary 
outcome measure for QoL (where 100 is the best possible 
score), the EORTC QLQ-c3035 so that those scoring above 
85 (who have high quality of life) will be excluded. This 
score was calculated using existing data examining the 
change in QoL scores for cancer survivors, where the lowest 
scoring two-thirds scored 87.1 or lower, with a median of 
80.936 (higher scores denoting higher QoL). Participants 
will be excluded if they have had sarcoma or lymphoma of 
the breast as these have a different course, prognosis and 
treatment, as agreed by the clinical members of the research 
team. Those living in the same household as another study 
participant will also be excluded to avoid potential contam-
ination across study groups.
sample size and power calculation
The primary outcome is QoL as measured by the total 
EORTC score at 6 months. The study is powered to 
detect a standardised effect size of 0.3, consistent with 
our previous internet-based behavioural interventions.37 
The key pairwise comparison is each of the two inter-
vention groups versus controls. To detect a difference 
of 0.3 standard mean difference in any pairwise compar-
ison between intervention and control for 80% power 
and alpha=0.05 requires 176 intervention participants in 
each intervention group and 176 controls, giving a total 
of 528 participants per cancer type. In order to explore 
the difference in the key subgroups (breast, colon and 
prostate cancers), this requires that we include 528 partic-
ipants in each of the three clinical groups. This gives a 
total of 1584 participants, or 1980 allowing for 20% loss to 
follow-up. Even though this is an individually randomised 
design cluster effects are possible: if we assume eight 
patients per intervention group per practice then to 
Table 1 Inclusion/exclusion criteria
Criteria
Screened 
by general 
practitioner
Screened 
online
Inclusions
Aged at least 18 years x x
Had a diagnosis of colorectal, 
breast or prostate cancer
x x
Finished primary cancer 
treatment within prior ten years/
diagnosis in prior ten years, 
unless on active surveillance for 
prostate cancer
x
Have internet access x
Impaired quality of life (≤85 on the 
EORTC)
x
Exclusions
Have had more than one type of 
cancer in the preceding 5 years
x x
Has metastatic cancer x
Has sarcoma or lymphoma of the 
breast
x
Receiving cancer treatment or 
had recent treatment (in last 
month)
x x
Expecting to start cancer 
treatment during the study period
x
Severe mental health problems 
and/or major uncontrolled 
depression/schizophrenia or 
dementia
x
Lives in the same household as 
another participant
x
Primary treatments can include bone marrow and stem cell 
transplants, breast-conserving surgery, chemotherapy, colostomy/
partial colostomy, immunotherapy, lumpectomy, mastectomy, 
orchidectomy, radical prostatectomy, radiotherapy, targeted 
therapy, trans-urethral resection.
EORTC, European Organization for Research and Treatment of 
Cancer.
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allow for clustering at a practice level and assuming an 
intraclass correlation coefficient (ICC) of 0.03 then 
the inflation factor is 1.21 (1+ (8–1*0.03)), which will 
require 2396 participants. Allowing for some leeway in 
our assumptions, we will aim to recruit approximately 835 
patients per cancer type (total n=2500).
randomisation and blinding
After online screening, patients will complete online 
consent and baseline measures. LifeGuide software will 
then randomise each participant to one of the three study 
groups using computer-generated random numbers. 
Once randomised, participants will be informed of their 
allocation and, if in one of the intervention arms, given 
access to Renewed. Randomisation will be stratified by 
cancer type: breast/prostate/colon and by EORTC score 
(high/low QoL; 64 or less/65–85 taking 65 as the lower 
25% CI from previous study data36). Blinding of rando-
misation is ensured by the use of automated computer 
software. Blinding of patients to the intervention is 
not possible. Participants will be informed online as to 
which group they have been allocated to immediately 
and will also be sent notification via email. Practice staff 
involved in the support arm of the trial will be notified 
by email when one of their patients is randomised to 
the Renewed + Support arm of the trial so that they can 
provide support.
renewed intervention
Participants randomised to the intervention groups will 
have access to their usual medical care and have access to 
the Renewed intervention.
The Renewed intervention was created using LifeGuide 
software ( www. lifeguideonline. org).38 39 During the devel-
opment of Renewed a synthesis of the growing evidence 
base was conducted that relates to digital interventions 
directed at improving QoL in cancer survivors.40 Consis-
tent with best practice in digital behaviour change inter-
vention development,41 42 iterative qualitative research 
was used to elicit user (patient and health professional) 
views and experiences of the intervention modules 
throughout development, including barriers and facil-
itators to engagement with altering diet and exercise.43 
The content of Renewed has been refined based on these 
findings.
See figure 2 for a detailed diagram showing the flow 
of participants through the intervention, incorporating 
Template for Intervention Description and Replication 
(TiDIER) guidelines.44 There are four interventions 
within Renewed that participants can choose to view: 
Getting Active for increasing physical activity, Healthy 
Paths for stress reduction, Eat for Health for diet improve-
ment and POWeR+45 for weight loss. In the introductory 
pages, Renewed provides participants with tailored sugges-
tions of the aspects of the website which might be most 
helpful to them, based on their answers to the baseline 
QoL measure (EORTC). There is also advice and infor-
mation about active surveillance/watchful waiting for 
prostate cancer for men being monitored. After the intro-
duction, participants are presented with their homepage 
containing buttons to the separate interventions with 
some brief information about what to expect from each; 
POWeR+ is only presented to participants who have a BMI 
of over 25.
Participants are able to come back to the interven-
tion and view which content they prefer as often as 
they choose. If a participant accesses one of these inter-
ventions they will be sent brief automated emails as 
reminders and for motivation with tips, interesting facts 
and brief information and advice. Content is tailored 
throughout Renewed, where appropriate, to present 
information most relevant to specific cancer types (eg, 
concerns about exercising with a colostomy bag) and 
the developers of the interventions worked together to 
ensure that conflicting advice is not given. Where appro-
priate, Renewed links to existing helpful websites rather 
than duplicating information: links to external resources 
are provided throughout the Renewed intervention, 
some of which are tailored by cancer type. For example, 
these include information about returning to work 
and connecting with other survivors of cancer (from 
the homepage) and links to websites providing further 
emotional support on Healthy Paths and websites about 
group exercise on Getting Active.
Getting Active
Getting Active is designed to help participants increase 
their physical activity. It includes a quiz designed to 
increase motivation for physical activity by highlighting 
the benefits of increasing activity. Getting Active encour-
ages gently increasing physical activity, taking a graded 
approach. Content addresses common barriers and 
concerns (eg, feeling tired, co-morbidities). There are 
various activity options such as exercising at home and 
walking. Users can set and review physical activity goals 
and receive tailored feedback on their progress.
Healthy Paths and Healthy Mind
Healthy Paths aims to reduce stress and improve psycho-
logical distress through the use of mindfulness-based and 
CBT techniques.46 It was amended for the current study 
to include specific information for cancer survivors about 
fear of recurrence and feelings of loss following cancer. 
The role of the stressor is acknowledged and patients 
are encouraged to use a variety of emotional regula-
tion strategies to develop effective coping skills. There 
are a number of mindfulness-based exercises as well as 
behavioural activation strategies47 and cognitive exercises 
focusing on emotion regulation (positive thought logging 
and self-compassion exercises).
Healthy Mind is a ‘lite’ version of Healthy Paths in the 
form of an app, which includes similar techniques to 
Healthy Paths (ie, CBT elements and mindfulness-based 
practices), but is for more general stress reduction and 
does not address cancer-specific concerns.
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POWeR+
POWeR+is an online weight management intervention, 
which has been shown to be effective and cost-effec-
tive, described in full elsewhere.45 In brief: Participants 
can follow a low-calorie or low-carbohydrate eating plan 
and can choose between increasing walking and any 
other physical activities. Participants set themselves goals 
and review weight, goals and plans on a weekly basis, 
receiving tailored feedback on progress. Participants also 
have access to 25 sessions, which include topics such as 
coping with cravings, gaining social support and relapse 
prevention.
Eat for Health
Eat for Health is based on a healthy diet (high in fruit and 
vegetables; reduced fat, sugar, alcohol, red and processed 
meats), which can reduce mortality rates in cancer survi-
vors.48 It differs from POWeR+ in that the focus is on eating 
a healthy diet rather than losing weight and is designed 
to enhance cancer survivor knowledge of healthy eating 
and increase motivation to make changes to eating habits. 
Eat for Health includes a short quiz about the benefits 
of healthy eating, an easy to follow eating plan using a 
traffic light system, patient stories modelling overcoming 
challenges, meal plans and healthy recipes. Participants 
are able to set, review and change their eating goals and 
receive personalised feedback on their progress.
renewed accompanied by brief human support
Participants in the Renewed group with accompanying 
brief human support will receive support from a nurse or 
healthcare assistant (at their surgery where possible, or else 
Figure 2 Renewed intervention outline.  o
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a central support facilitator or research nurse employed by 
the study team where the practice are unable to provide 
their own support). ‘Supporters’ are able to view the 
Renewed intervention but do not need specific knowledge 
of Renewed content: Supporters will receive brief web-based 
training to learn how to provide support using the CARE 
approach (Congratulate, Ask, Reassure, Encourage49 50), 
which aims to help build patients’ autonomous motiva-
tion for engaging with the digital intervention and offline 
behavioural changes (eg, getting more active).
Three 10 minute support sessions will be offered 
in person, by phone or email. The first will be offered 
2 weeks after initially logging on to Renewed. Supporters 
are also asked to send encouraging, supportive emails 
at weeks 2 and 4 after randomisation and templates are 
supplied for this. Follow-up support will be offered at 4 
and 8 weeks after baseline. Not all participants will want 
support and they can choose whether or not to contact 
their Supporter; Supporters will keep a record of the 
frequency and nature of support they provide to partic-
ipants. Participants can contact their Supporter through 
the website. Number and type (email/phone/face-to-
face) of support contacts, as well as length of appoint-
ments, will be recorded.
usual care
Participants allocated to usual care will receive a link to 
the National Health Service's (NHS) LiveWell website 
where they can access advice about living a healthier life-
style. Other than this, participants in the usual care group 
will continue to use their existing medical support as they 
usually would. At the end of the study, participants will 
be asked what other interventions, if any, they have used 
while taking part in the study.
data collection
Participants will receive three automated notifications 
to complete follow-up measures at 6 and 12 months, 
one being the initial invitation to ask them to complete 
the online questionnaires and reminders at 1 week and 
2 weeks later if they are not complete. Participants will 
receive a £10 gift voucher via email when they complete 
the 6 month follow-up questionnaires online. If, after 
6 weeks, participants have not completed the 6 month 
follow-up questionnaires online, paper-based question-
naires will be sent with a £10 gift voucher for high-street 
stores (regardless of paper-based questionnaire comple-
tion). If paper-based questionnaires are not returned 
after 2 weeks of being sent, research staff (blind to group 
allocation) will phone participants to request limited 
responses over the phone (the EORTC); a maximum of 
two phone contacts per participant will be made. The 
procedure will be the same for 12 month follow-ups but 
with no further vouchers given. If at any stage the partici-
pant indicates that they would not be willing to complete 
any further measures, no further contact will be made 
regarding the follow-ups. At study completion, the usual 
care (wait list) group will be given access to the Renewed 
website. Participants will be asked if they would like a copy 
of the study results, and if so whether they would prefer to 
receive these by email or post.
Sub-study examining follow-up questionnaire design
There has been extensive research into how the design 
and presentation of questionnaires affects response rates 
and response quality (see51 for an overview). Two versions 
of the 12 month outcome measures will be used, to test 
whether completion rates can be increased by enhanced 
presentation. Users will be randomised to either the 
control (‘normal’) outcome measures or the enhanced 
outcome measures. For both versions, the wording and 
scales will remain the same, but the presentation (eg, 
use of images, page layout and messages encouraging 
completion) will be altered for the enhanced version.
Measures
Table 2 presents a list of the measures and when they will 
be presented to participants. Measures will be collected 
via the website.
Table 2 Measures and times presented
Measure Baseline
Six 
months 12 Months
Primary outcome
EORTC QLQ-c30 x x x
Secondary outcomes
HADS x x
FRRS x x
EQ-5D-5L x x x
PA x
MYCAW x x
Personal costs 
data for heath 
economics
x
Process measures
TAQ x
PEI x
Website 
satisfaction and 
usage
x
PETS x
Usage of other 
interventions 
during past year
x
Demographics include gender, age, marital status, years of 
education, ethnicity, height and weight and are taken at baseline;
EQ-5D-5L, Euro-Qol; EORTC QLQ-c30, European Organization 
for Research and Treatment of Cancer Quality of Life 
Questionnaire-c30 as primary outcome; FRRS, Fear of Relapse/
Recurrence Scale; HADS, Hospital Anxiety and Depression Scale; 
MYCAW, Measure Yourself Concerns and Well-being; PA, Physical 
activity checker; PEI, Patient Enablement Instrument; Website 
satisfaction measure; PETS, Problematic Experiences of Therapy 
Scale; TAQ, Treatment Appraisal Questionnaire.
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The primary outcome of QoL will be measured using 
the total score on the EORTC QLQ-c30.35 The EORTC has 
30 items and contains five functioning subscales: physical, 
emotional, social, role and cognitive and eight symptom 
subscales: pain, fatigue, nausea and vomiting, dyspnea, 
sleep problems, loss of appetite, constipation and diar-
rhoea, financial impact and overall quality of life. Each 
item has a four-point response scale from ‘not at all’ to ‘very 
much’ and scores are calculated using a linear conversion 
to create a score from 0 to 100. It is one of the most widely 
used measures for health-related QoL in cancer research.52
The Fear of Relapse/Recurrence Scale53 has been modi-
fied to three items so that ‘I will probably have a relapse 
in the next 5 years’ and ‘I am certain that I have been 
cured of cancer’ are omitted as they do not apply to those 
on Active Surveillance. The Patient Enablement Instru-
ment (PEI) was modified so that it asks about confidence 
and understanding relating to health as a result of using 
the website as opposed to receiving support from a doctor 
(PEI54 55). Data regarding website and/or app usage (eg, 
pages accessed, time spent on each page) will be down-
loaded using LifeGuide software. A medical record notes 
review will be conducted after 12 month follow-up to 
extract NHS and Personal Social Service use. This will 
enable collection of data pertaining to clinical status 
including cancer recurrence. Online questions will be 
used to collect patients’ personal costs. The EQ-5D-5L56 57 
which measures medical QoL (QALY) will be collected at 
baseline, 6 months and 12 months. We will apply the UK 
tariff to translate the EQ-5D-5L to utility scores.
statistical analysis
SPSS, Stata and Excel software will be used to evaluate 
outcomes. All participant data will be analysed, including 
those who have withdrawn, unless participant/s specifically 
request that their data be removed from the data set. All 
participants will be analysed on an intention to treat basis, 
that is, as randomised with any missing data imputed using 
a chained equations multiple imputation model. Complete 
cases analysis will be undertaken as a sensitivity analysis.
Linear regression models will be used for the analysis 
of continuous variables, controlling for baseline values, 
stratification variables, practice as a cluster variable, and 
also controlling for potential confounding variables as 
appropriate, both for the overall trial sample and for each 
clinical subgroup (breast, prostate, colon). Results will 
be produced for the trial overall and within each cancer 
type. We will undertake pre-specified subgroup analyses, 
including exploring possible mediators and moderators in 
the context of the process analysis. These analyses will be set 
out in full in the Statistical Analysis Plan prior to the final 
follow-ups.
To examine how the design and presentation of 
questionnaires affects response rates and response 
quality, we will compare the initial completion rate for 
the control outcome measures versus the enhanced 
outcome measures using a factorial design where partic-
ipants will be allocated to see the normal or enhanced 
questionnaires. A ratio of 1:2 (normal:enhanced) will be 
used when allocating participants to get a feel for how the 
enhanced questionnaire presentation might impact on 
study completion, given that unenhanced questions are 
already presented at baseline and 6 months.
Health economics
Published unit costs (Personal Social Services Research 
Unit, British National Formulary and national refer-
ence costs) will be applied to itemised resource usage in 
calculating total cost per person. The health economic 
analysis will include cost effectiveness (£/unit of primary 
outcome) and cost utility (£/EQ-5D-5L QALY) analysis. 
The costs of the study will be from an NHS perspective 
with exploration of a quasi-social perspective including 
the time required by patients interacting with the inter-
vention. The study will identify and quantify the resources 
required to deliver the intervention, and any impact on 
NHS service usage and personal costs. We will explore 
the potential change in NHS service use and change in 
the pattern of use of such services, such as whether the 
new intervention will reduce medication (eg, depression 
related drugs), GP consultations and community nurse 
and special service usage. The key resource usage of 
the intervention covers nursing support time, software. 
Personal costs will be collected on time off work (both 
patients/carers), cost of use of internet (personal time) 
and costs of over-the-counter medications. The economic 
analyses of both costs, QoL (EORTC and QALY), provided 
minimally  worthwhile improvements are shown, will be 
summarised in terms of incremental cost effectiveness 
ratios and cost effectiveness acceptability curves.
Qualitative process studies
There will be two qualitative process studies. One will 
examine participants’ experiences of using the interven-
tion and participating in the trial. Participants will be 
emailed the information sheet with an invitation to take 
part in this additional study. Eight to ten participants per 
cancer type (n=24–30) will be purposively sampled until 
saturation (by cancer type, age and gender). Participants 
will be invited to take part after they have taken part in 
the trial for at least 1–2 months. Additional consent will 
be sought for these studies. Interviews (face-to-face or 
by phone) will consist of open-ended questions to elicit 
detailed responses. Each interview will last approximately 
60 min. These interviews will enable the research team 
to further assess the acceptability and helpfulness of the 
intervention and any barriers to engagement. Control 
participants will also be invited in the same way to partici-
pate in brief interviews to elicit qualitative feedback about 
the brief advice link they were given at baseline (the NHS 
LiveWell website) and the study.
The second qualitative process study will be conducted 
with Supporters, to explore their views of supporting 
patients in using Renewed online. This study will elicit 
perceptions of the initial training website, providing 
support to patients and the general study procedures. 
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After at least 1–2 months of participation, support 
providers, GPs and any other primary care staff signifi-
cantly involved in trial procedures or intervention delivery 
(n=20, or until saturation) will be invited to take part in 
this additional study. Focus groups, interviews or phone 
interviews will be held, depending on availability or else 
electronic (written) feedback will be requested.
In both process studies interviews will be recorded and 
fully transcribed. Transcriptions will be anonymised. To 
ensure that we remain open to, and grounded in, inter-
viewee perspectives we will carry out inductive thematic 
analysis of all textual data,58 triangulated where appro-
priate with other trial data (eg, web usage), and with 
discussion among team members (including our PPI 
representatives) to elaborate our interpretations.58
handling of adverse events
It is very unlikely that there will be any adverse events 
during screening and questionnaire completion, given that 
screening online consists of answering questions; however, 
participants are repeatedly told that they can contact the 
research team who can signpost them to other support 
services as appropriate. Participants have the right to 
withdraw from the study at any time. If a participant with-
draws having completed questionnaires, their data will be 
retained to evaluate potential differences and reasons for 
attrition, unless they ask us not to use their data. Should a 
participant be ineligible for the study for any reason, they 
are presented with a page of alternative support services.
Any serious adverse event (SAE) occurring to a 
research participant will be reported to the Ethics 
Committee where, in the opinion of the Chief Investi-
gator, the event was related to administration of any 
of the research procedures, and was an unexpected 
occurrence. Non-serious AEs will not be collected. 
Pre-planned hospitalisation for example, for pre-existing 
conditions which have not worsened or elective proce-
dures for a pre-existing condition will not be classed as 
an SAE. GP surgeries will inform the research team and/
or the clinical trials unit of any SAEs within 24 hours of 
becoming aware of the event occurring. GP surgeries will 
be provided with a standard operating procedure and a 
form for SAE reporting. Reports of SAEs will be provided 
to the Committee within 15 days of the Chief Investigator 
becoming aware of the event. All SAEs will also be sent to 
the Trial Steering Committee.
dissemination
The results of this trial will be published in peer-reviewed jour-
nals and through conference presentations. Press releases 
will be utilised to disseminate the findings to the general 
public and the findings will also be sent to the GP surgeries 
who participate and to those participants who request them. 
Social media networks connected to the research group (eg, 
Twitter) will be used to disseminate published research. If 
proven effective, Renewed will be developed with service 
providers and charities to explore mechanisms through 
which it can be made available to patients.
Author affiliations
1Department of Psychology, University of Southampton, Southampton, UK
2School of Health Sciences, University of Southampton, Southampton, UK
3Primary Care and Population Sciences Division, University of Southampton, 
Southampton, UK
4Biostatistics Research Group, University of Leicester, Leicester, UK
5Patient and Public Involvement team for the CLASP project
6Mathematical Sciences, University of Southampton, Southampton, UK
7Southampton Clinical Trials Unit, University of Southampton, Southampton, UK
8Macmillan Survivorship Research Group, University of Southampton, Southampton, 
UK
9Saw Swee Hock Public School of Health, National University of Singapore, 
Singapore
10Leeds Institute of Health Sciences, University of Leeds, Leeds, UK
11Dorset Cancer Centre, Poole, UK
12Southern Health NHS Foundation Trust, Southampton, UK
13School of Nursing and Midwifery, Oxford Brookes University, Oxford, UK
14Faculty of Health & Life Sciences, Coventry University, Coventry, UK
15School of Health Sciences, Bangor University, Bangor, UK
16School of Experimental Psychology, University of Bristol, Bristol, UK
Acknowledgements  The trial team would like to thank Julie Hooper, Megan 
Liddiard and Karen Middleton for their assistance with the recruitment of GP 
surgeries. Eat for Health was largely developed by Tara Cheetham-Blake in 
collaboration with Joanna Slodkowska-Barabasz, also of the University of 
Southampton. We would also like to thank Kirsten Smith, Mary Steele and Jin Zhang 
of the University of Southampton for their work on programming Renewed Online. 
We would like to thank all of our PPIs who helped in discussions surrounding the 
study procedures and helped us to develop our intervention on the project: Tamsin 
Burford, Geoff Sharman, Kevin Summers, Roger Bacon and other members of the 
PPI team who wish to remain anonymous.
Contributors AK drafted the manuscript with input from all authors. LY and PL 
designed the study and secured funding. LY and KB led the overall development of 
Renewed online. LY, AK, KB, JB, and TeC developed procedures for the study design 
with help from LW. LY and KB oversaw the development of all of the intervention 
and had final approval of all content. AK and AWAG developed resources for Healthy 
Paths. AM, KS and TeC developed resources for Getting Active. TaC-B developed 
additional content for men on Active Surveillance. All co-authors and PPI reps (RB, 
GL, GS, KS) also provided input into the development of Renewed. BS wrote the 
statistical analysis plan. GLY wrote the plan for the health economic analysis. DB, 
DE, CF, RDN, RO, SR, AR, EW and CW contributed to the study design as part of 
the management team and contributed to the final version of the manuscript. All 
authors approved the final manuscript. AK is the guarantor.
Funding This project is funded by the National Institute for Health Research (NIHR) 
[Programme Grants for Applied Research Programme/Reference Number RP-PG-
0514-20001]. The views expressed are those of the authors and not necessarily 
those of the NIHR or the Department of Health and Social Care (See page 39).
Competing interests None declared. 
Patient consent for publication Not required.
Ethics approval This trial was approved in March 2017 by Ethics and Research 
Governance in Southampton, ID 25160 and has been approved by the NHS 
Research Ethics Committee via the Integrated Research Application System, ID 
238636, N/RES Reference 18/NW/0013.
Provenance and peer review Not commissioned; externally peer reviewed.
open access This is an open access article distributed in accordance with the 
Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits 
others to copy, redistribute, remix, transform and build upon this work for any 
purpose, provided the original work is properly cited, a link to the licence is given, 
and indication of whether changes were made. See: https:// creativecommons. org/ 
licenses/ by/ 4. 0/.
rEFErEnCEs
 1. Foster C, Wright D, Hill H, et al. Psychosocial implications of living 5 
years or more following a cancer diagnosis: a systematic review of 
the research evidence. Eur J Cancer Care 2009;18:223–47.
 2. Elliott J, Fallows A, Staetsky L, et al. The health and well-being of 
cancer survivors in the UK: findings from a population-based survey. 
Br J Cancer 2011;105:S11–20.
 o
n
 15 April 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024862 on 1 March 2019. Downloaded from 
10 Krusche A, et al. BMJ Open 2019;9:e024862. doi:10.1136/bmjopen-2018-024862
Open access 
 3. Richards M. Quality of life of cancer survivors in England: Report on 
a pilot survey using Patient Reported Outcome Measures (PROMS). 
2012.
 4. Foster C, Calman L, Richardson A, et al. Improving the lives of 
people living with and beyond cancer: Generating the evidence 
needed to inform policy and practice. J Cancer Policy 2018;15:92–5.
 5. Armes J, Crowe M, Colbourne L, et al. Patients' supportive 
care needs beyond the end of cancer treatment: a prospective, 
longitudinal survey. J Clin Oncol 2009;27:6172–9.
 6. Morton LM, Onel K, Curtis RE, et al. The rising incidence of second 
cancers: patterns of occurrence and identification of risk factors for 
children and adults. Am Soc Clin Oncol Educ Book 2014:e57–e67.
 7. Coleman MP, Forman D, Bryant H, et al. Cancer survival in 
Australia, Canada, Denmark, Norway, Sweden, and the UK, 
1995–2007 (the International Cancer Benchmarking Partnership): 
an analysis of population-based cancer registry data. The Lancet 
2011;377:127–38.
 8. Schwedhelm C, Boeing H, Hoffmann G, et al. Effect of diet on 
mortality and cancer recurrence among cancer survivors: a 
systematic review and meta-analysis of cohort studies. Nutr Rev 
2016;74:737–48.
 9. Cummings A, Grimmett C, Calman L, et al. Comorbidities are 
associated with poorer quality of life and functioning and worse 
symptoms in the 5 years following colorectal cancer surgery: 
Results from the ColoREctal Well-being (CREW) cohort study. 
Psychooncology 2018;27:2427–35.
 10. van de Poll-Franse LV, Mols F, Vingerhoets AJ, et al. Increased health 
care utilisation among 10-year breast cancer survivors. Support Care 
Cancer 2006;14:436–43.
 11. Halfdanarson TR, Thordardottir E, West CP, et al. Does dietary 
counseling improve quality of life in cancer patients? A systematic 
review and meta-analysis. J Support Oncol 2008;6:234–7.
 12. Kangas M, Bovbjerg DH, Montgomery GH. Cancer-related fatigue: 
a systematic and meta-analytic review of non-pharmacological 
therapies for cancer patients. Psychol Bull 2008;134:700–41.
 13. Mishra SI, Scherer RW, Geigle PM, et al. Exercise interventions on 
health-related quality of life for cancer survivors. Cochrane Database 
Syst Rev 2012:CD007566.
 14. Piet J, Würtzen H, Zachariae R. The effect of mindfulness-based 
therapy on symptoms of anxiety and depression in adult cancer 
patients and survivors: a systematic review and meta-analysis. J 
Consult Clin Psychol 2012;80:1007–20.
 15. Courneya KS, Katzmarzyk PT, Bacon E. Physical activity and obesity 
in Canadian cancer survivors. Cancer 2008;112:2475–82.
 16. Cramp F, Byron-Daniel J. Exercise for the management of 
cancer-related fatigue in adults. Cochrane Database Syst Rev 
2012;11:CD006145.
 17. Speck RM, Courneya KS, Mâsse LC, et al. An update of controlled 
physical activity trials in cancer survivors: a systematic review and 
meta-analysis. J Cancer Surviv 2010;4:87–100.
 18. Duncan M, Moschopoulou E, Herrington E, et al. Review of 
systematic reviews of non-pharmacological interventions to improve 
quality of life in cancer survivors. BMJ Open 2017;7:e015860.
 19. Davies NJ, Batehup L, Thomas R. The role of diet and physical 
activity in breast, colorectal, and prostate cancer survivorship: a 
review of the literature. Br J Cancer 2011;105(Suppl 1):S52–73.
 20. Battaglini CL, Mills RC, Phillips BL, et al. Twenty-five years of 
research on the effects of exercise training in breast cancer survivors: 
a systematic review of the literature. World J Clin Oncol 2014;5:177.
 21. Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and 
physical activity guidelines for cancer survivors. CA: A Cancer 
Journal for Clinicians 2012;62:242–74.
 22. Osborn RL, Demoncada AC, Feuerstein M. Psychosocial 
interventions for depression, anxiety, and quality of life in cancer 
survivors: meta-analyses. Int J Psychiatry Med 2006;36:13–34.
 23. Nyklícek I, Kuijpers KF. Effects of mindfulness-based stress reduction 
intervention on psychological well-being and quality of life: is 
increased mindfulness indeed the mechanism? Ann Behav Med 
2008;35:331–40.
 24. Matchim Y, Armer JM, Stewart BR. Mindfulness-based stress 
reduction among breast cancer survivors: a literature review and 
discussion. Oncol Nurs Forum 2011;38:E61–71.
 25. Crane-Okada R, Kiger H, Sugerman F, et al. Mindful movement 
program for older breast cancer survivors: a pilot study. Cancer Nurs 
2012;35:E1–13.
 26. Johns SA, Brown LF, Beck-Coon K, et al. Randomized controlled 
pilot study of mindfulness-based stress reduction for persistently 
fatigued cancer survivors. Psychooncology 2015;24:885–93.
 27. van der Lee ML, Garssen B. Mindfulness-based cognitive therapy 
reduces chronic cancer-related fatigue: a treatment study. 
Psychooncology 2012;21:264–72.
 28. Blackburn GL, Wang KA. Dietary fat reduction and breast cancer 
outcome: results from the Women's Intervention Nutrition Study 
(WINS). Am J Clin Nutr 2007;86:878S–81.
 29. Kassianos AP, Raats MM, Gage H, et al. Quality of life and dietary 
changes among cancer patients: a systematic review. Qual Life Res 
2015;24:705–19.
 30. Karahalios A, English DR, Simpson JA. Weight change and risk of 
colorectal cancer: a systematic review and meta-analysis. Am J 
Epidemiol 2015;181:832–45.
 31. Vance V, Mourtzakis M, McCargar L, et al. Weight gain in breast 
cancer survivors: prevalence, pattern and health consequences. 
Obes Rev 2011;12:282–94.
 32. Reeves MM, Terranova CO, Eakin EG, et al. Weight loss intervention 
trials in women with breast cancer: a systematic review. Obes Rev 
2014;15:749–68.
 33. Stellefson M, Chaney B, Barry AE, et al. Web 2.0 chronic disease 
self-management for older adults: a systematic review. J Med 
Internet Res 2013;15:e35.
 34. Cuijpers P, Riper H, Andersson G. Internet-based treatment of 
depression. Curr Opin Psychol 2015;4:131–5.
 35. Aaronson NK, Ahmedzai S, Bergman B, et al. The European 
Organization for Research and Treatment of Cancer QLQ-C30: a 
quality-of-life instrument for use in international clinical trials in 
oncology. J Natl Cancer Inst 1993;85:365–76.
 36. Foster C, Haviland A, Winter J, et al. Trajectories of quality of life, 
health status and personal well-being up to two years after curative 
intent treatment for colorectal cancer: results from the UK ColoREctal 
Wellbeing (CREW) cohort study. Psycho-Oncology 2016:2.
 37. Giesinger JM, Kieffer JM, Fayers PM, et al. EORTC Quality of 
Life Group. Replication and validation of higher order models 
demonstrated that a summary score for the EORTC QLQ-C30 is 
robust. J Clin Epidemiol 2016;69(Supplement C):79–88.
 38. Yardley L, Osmond A, Hare J, et al. Introduction to the LifeGuide: 
software facilitating the development of interactive behaviour change 
internet interventions. 2009.
 39. Hare J, Osmond A, Yang Y, et al. LifeGuide: A platform for performing 
web-based behavioural interventions. 2009.
 40. Corbett T, Singh K, Payne L, et al. Understanding acceptability of 
and engagement with Web-based interventions aiming to improve 
quality of life in cancer survivors: A synthesis of current research. 
Psychooncology 2018;27:22–33.
 41. Bradbury K, Watts S, Arden-Close E, et al. Developing digital 
interventions: a methodological guide. Evid Based Complement 
Alternat Med 2014;2014:1–7.
 42. Yardley L, Morrison L, Bradbury K, et al. The person-based approach 
to intervention development: application to digital health-related 
behavior change interventions. J Med Internet Res 2015;17:e30.
 43. Corbett T, Cheetham T, Müller AM, et al. Exploring cancer survivors' 
views of health behaviour change: "Where do you start, where do 
you stop with everything?". Psychooncology 2018;27:1816–24.
 44. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of 
interventions: template for intervention description and replication 
(TIDieR) checklist and guide. BMJ 2014;348:g1687.
 45. Little P, Stuart B, Hobbs FR, et al. An internet-based intervention with 
brief nurse support to manage obesity in primary care (POWeR+): 
a pragmatic, parallel-group, randomised controlled trial. Lancet 
Diabetes Endocrinol 2016;4:821–8.
 46. Geraghty AW, Muñoz RF, Yardley L, et al. Developing an Unguided 
Internet-Delivered Intervention for Emotional Distress in Primary Care 
Patients: Applying Common Factor and Person-Based Approaches. 
JMIR Ment Health 2016;3:e53.
 47. Cuijpers P, van Straten A, Warmerdam L. Behavioral activation 
treatments of depression: a meta-analysis. Clin Psychol Rev 
2007;27:318–26.
 48. Schwingshackl L, Hoffmann G. Adherence to Mediterranean diet and 
risk of cancer: an updated systematic review and meta-analysis of 
observational studies. Cancer Med 2015;4:1933–47.
 49. Bradbury K, Morton K, Band R, et al. Understanding how primary 
care practitioners perceive an online intervention for the management 
of hypertension. BMC Med Inform Decis Mak 2017;17:5.
 50. Smith E, Bradbury K, Scott L, et al. Providing online weight 
management in Primary Care: a mixed methods process evaluation 
of healthcare practitioners' experiences of using and supporting 
patients using POWeR. Implement Sci 2017;12:69.
 51. Dillman DA, Smyth JD, Christian LM. Internet, phone, mail, and 
mixed-mode surveys: the tailored design method: John Wiley & 
Sons, 2014.
 52. Giesinger JM, Kuijpers W, Young T, et al. Thresholds for clinical 
importance for four key domains of the EORTC QLQ-C30: physical 
functioning, emotional functioning, fatigue and pain. Health Qual Life 
Outcomes 2016;14:87.
 o
n
 15 April 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024862 on 1 March 2019. Downloaded from 
11Krusche A, et al. BMJ Open 2019;9:e024862. doi:10.1136/bmjopen-2018-024862
Open access
 53. Greenberg DB, Kornblith AB, Herndon JE, et al. Quality of life 
for adult leukemia survivors treated on clinical trials of cancer 
and leukemia group B during the period 1971-1988. Cancer 
1997;80:1936–44.
 54. Howie JG, Heaney DJ, Maxwell M, et al. Quality at general  
practice consultations: cross sectional survey. BMJ  
1999;319:738–43.
 55. Little P, Lewith G, Webley F, et al. Randomised controlled trial of 
Alexander technique lessons, exercise, and massage (ATEAM) for 
chronic and recurrent back pain. BMJ 2008;337:a884.
 56. Herdman M, Gudex C, Lloyd A, et al. Development and preliminary 
testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life 
Res 2011;20:1727–36.
 57. van Hout B, Janssen MF, Feng YS, et al. Interim scoring for the EQ-
5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 
2012;15:708–15.
 58. Joffe H, Yardley L. 4. Content and thematic analysis. Research 
methods for clinical and health psychology. California: Sage, 
2004:56–68.
 o
n
 15 April 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-024862 on 1 March 2019. Downloaded from 
